Diamonds in the Rough
Cross-referencing fundamental value against technical exhaustion to isolate beaten-down XLV constituents that screen cheap and oversold. The bottom-right quadrant — high earnings yield, low RSI — is the prime hunting ground, especially where money flow (MFI) shows quiet accumulation despite the falling price.
Educational screen, not investment advice. “Diamond” classification is a mechanical valuation-vs-RSI split around the cohort median earnings yield and an RSI of 50.
Alpha Quadrant — Valuation × Technical Exhaustion
X = earnings yield (cheaper right) · Y = RSI 14 (more oversold lower) · bubble = market cap · color = money flow.
Diamond Candidates
Ranked by a composite of earnings yield, ROIC, oversold RSI, recent weakness, and improving money flow.
| # | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | DVA | DaVita Inc. | 70.5 | 9.41% | 0.55 | 30 | -24.51% | 36 | grey |
| 2 | CI | The Cigna Group | 55.0 | 8.60% | -- | 49 | -3.57% | 71 | distress |
| 3 | PODD | Insulet Corporation | 51.9 | 4.51% | 0.23 | 43 | -13.63% | 54 | safe |
| 4 | ELV | Elevance Health, Inc. | 49.2 | 7.06% | 0.26 | 53 | +5.30% | 66 | safe |
| 5 | ALGN | Align Technology Inc | 49.1 | 5.33% | 0.30 | 39 | -3.52% | 38 | safe |
| 6 | PFE | Pfizer Inc. | 47.8 | 6.43% | 0.56 | 73 | +16.28% | 72 | safe |
| 7 | UHS | Universal Health Services, Inc. Class B | 47.4 | 13.20% | 0.28 | 64 | +11.95% | 64 | safe |
| 8 | GEHC | GE HealthCare Technologies Inc. Common Stock | 46.8 | 7.25% | 0.60 | 62 | +19.13% | 57 | grey |
| 9 | INCY | Incyte Genomics Inc | 45.8 | 7.32% | 0.34 | 68 | +10.24% | 60 | safe |
| 10 | BMY | Bristol-Myers Squibb Co. | 45.3 | 5.80% | 0.63 | 65 | +8.85% | 65 | safe |
| 11 | UNH | UNITEDHEALTH GROUP INCORPORATED (Delaware) | 44.3 | 4.71% | 0.38 | 44 | -6.13% | 33 | safe |
| 12 | RMD | ResMed Inc. | 43.6 | 5.56% | 0.58 | 67 | +19.92% | 72 | safe |
| 13 | ZTS | ZOETIS INC. | 43.5 | 8.99% | 0.43 | 54 | +1.66% | 51 | safe |
| 14 | GILD | Gilead Sciences Inc | 42.7 | 4.89% | 0.83 | 70 | +13.56% | 81 | safe |
| 15 | DGX | Quest Diagnostics Inc. | 41.6 | 5.06% | 0.63 | 74 | +8.21% | 69 | safe |
Short-Squeeze Watch
Constituents with the highest composite squeeze score — heavy short interest meeting price support.
| # | |||||||
|---|---|---|---|---|---|---|---|
| 1 | MRNA | Moderna, Inc. Common Stock | 73.5 | 13.78% | 10.22 | +190.10% | high |
| 2 | RMD | ResMed Inc. | 61.8 | 10.90% | 14.19 | +19.92% | high |
| 3 | DVA | DaVita Inc. | 48.9 | 6.83% | 7.51 | -24.51% | elevated |
| 4 | INCY | Incyte Genomics Inc | 44.9 | 6.16% | 4.80 | +10.24% | elevated |
| 5 | HSIC | Henry Schein Inc | 44.0 | 6.48% | 4.71 | +4.27% | elevated |
| 6 | HCA | HCA Healthcare, Inc. | 42.5 | 3.44% | 3.53 | +11.76% | elevated |
| 7 | VEEV | Veeva Systems Inc. | 40.9 | 5.02% | 5.04 | +29.37% | elevated |
| 8 | MCK | McKesson Corporation | 40.6 | 3.01% | 3.84 | +7.51% | elevated |
| 9 | VTRS | Viatris Inc. Common Stock | 40.6 | 3.99% | 4.80 | -3.63% | elevated |
| 10 | UHS | Universal Health Services, Inc. Class B | 40.5 | 6.91% | 2.63 | +11.95% | elevated |
| 11 | BDX | Becton, Dickinson and Co. | 39.9 | 3.65% | 5.73 | +20.81% | elevated |
| 12 | CRL | Charles River Laboratories International, Inc. | 39.6 | 7.19% | 4.06 | +31.78% | elevated |
Market cap, valuation, and short-interest metrics are joined to the latest XLV holdings snapshot; each ticker links to its full quote and analysis page.